恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液研究进展

Research progress in the treatment of non-small cell lung cancer with malignant pleural effusion by endostar combined with cisplatin infusion

关键词:  非小细胞肺癌  恶性胸腔积液  恩度  顺铂

Key words:  [Key words]　non-small cell lung cancer  malignant pleural effusions  endostar  cisplatin

摘要:

[摘要]　恶性胸腔积液是晚期非小细胞肺癌常见并发症，严重影响肿瘤患者生活质量。重组人血管内皮抑素注射液(恩度)自2006年国家食品药品监督管理局批准上市以来，其与顺铂联合行胸腔内灌注治疗非小细胞肺癌合并恶性胸腔积液的患者，取得了值得肯定的疗效，且安全性较好。本文回顾了近年恩度联合顺铂方案胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的文献，就其最新进展进行综述。

Abstract:

[Abstract]　Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC) and has seriously impacts on patient's quality of life. Recombinant human endostatin injection (Endostar), SFDA approved since 2006, combined with cisplatin intrapleural perfusion showed good effectivity and good safety for the treatment of NSCLC patients with MPE. The recent clinical research of Endostar combined with cisplatin intrapleural perfusion for the treatment of NSCLC MPE are reviewed.